In other studies, humanized antibody designed to target tumor cells by binding to a TNFR stimulatory receptor (CD137) on immune cells to promote anti-tumor immunity responses (Qi et al., 2019) such as Urlumab (Segal et al., 2017) was also associated with liver toxicity, inflammation and liver related adverse events. Here, TNFRSF9 is linked to neoplasm.